Fig. 4: LAG-3 expression in pretreatment samples from pembrolizumab-treated advanced non-small-cell lung carcinoma patients. | Modern Pathology

Fig. 4: LAG-3 expression in pretreatment samples from pembrolizumab-treated advanced non-small-cell lung carcinoma patients.

From: Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance

Fig. 4

A Distribution of primary and metastatic pretreatment samples in the pembrolizumab-treated patient cohort (n = 38 with evaluable LAG-3). Met metastasis, LN lymph node. B LAG-3 (left), CD8 (middle), and LAG-3/CD8 index (right) in the pembrolizumab-treated (IO) and non-IO cohorts. Bars represent medians and 95% confidence intervals. C Progression-free (top) and overall (bottom) survival in the IO cohort stratified by LAG-3, CD8, and LAG-3/CD8. “Low” and “high” refer to ≤ and >median, respectively. Sample sizes represent the number at risk at time 0.

Back to article page